{"id":181260,"date":"2026-02-18T01:19:15","date_gmt":"2026-02-18T06:19:15","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=181260"},"modified":"2026-02-18T01:19:15","modified_gmt":"2026-02-18T06:19:15","slug":"lincoln-pharmaceuticals-profit-increases-37-7-in-third-quarter","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/lincoln-pharmaceuticals-profit-increases-37-7-in-third-quarter\/","title":{"rendered":"Lincoln Pharmaceuticals profit increases 37.7% in third quarter"},"content":{"rendered":"\n

Lincoln Pharmaceuticals Ltd (LINCOLN:NSE, 531633:BSE)<\/strong> shares closed at \u20b9618.60<\/strong> on Wednesday, representing a 1.26%<\/strong> decline from the previous session’s close. The pharmaceutical manufacturer’s equity performance follows the release of its financial results for the quarter ended December 31, 2025 (Q3 2026).<\/p>\n\n\n\n

Market Capitalization<\/strong><\/h2>\n\n\n\n

As of February 18, 2026, the market capitalization of Lincoln Pharmaceuticals stands at \u20b91,239.09 crore<\/strong> ($149.6 million).<\/p>\n\n\n\n

Latest Quarterly Results<\/strong><\/h2>\n\n\n\n

Lincoln Pharmaceuticals reported consolidated revenue from operations of \u20b9166.32 crore<\/strong> for the third quarter of fiscal year 2026, a 13.49%<\/strong> increase compared to \u20b9146.55 crore in the same period last year. Consolidated net profit for the quarter rose 37.70%<\/strong> year-on-year to \u20b928.60 crore<\/strong>, up from \u20b920.77 crore.<\/p>\n\n\n\n

Earnings before interest, tax, depreciation, and amortization (EBITDA) reached \u20b938.74 crore<\/strong>, up 18.73%<\/strong> from \u20b932.63 crore. The company does not report specific revenue under O2C, Digital, or Retail segments. Its operations are unified under the pharmaceutical formulations business, with a focus on chronic therapies and export markets.<\/p>\n\n\n\n

\n\n\n\n

FINANCIAL TRENDS<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\n\n\n\n

Nine-Month Overview<\/strong><\/h2>\n\n\n\n

For the nine months ended December 31, 2025 (9M FY26), consolidated revenue from operations reached \u20b9483.75 crore<\/strong>, compared to \u20b9455.05 crore in 9M FY25. Net profit for the nine-month period stood at \u20b976.26 crore<\/strong>, an increase from \u20b970.77 crore in the previous year. Financial indicators for the nine-month period reflect a trend of growth in both revenue and profitability.<\/p>\n\n\n\n

Business & Operations Update<\/strong><\/h2>\n\n\n\n

The company maintained a portfolio of over 1,700 registered products<\/strong> across 15 therapeutic segments. Managing Director Mahendra Patel<\/strong> confirmed the company\u2019s focus on the cardiac, diabetic, dermatology, and ENT segments. On January 9, 2026, CRISIL Limited<\/strong> reaffirmed the company\u2019s long-term credit rating at CRISIL A\/Stable<\/strong> and short-term rating at CRISIL A1<\/strong>.<\/p>\n\n\n\n

Q&A Session Focal Points<\/strong><\/h2>\n\n\n\n

During the discussions following the results announcement, management addressed several operational aspects:<\/p>\n\n\n\n

    \n
  • Revenue Targets:<\/strong> Management reiterated a target of reaching \u20b91,000 crore in revenue within the next three years.<\/li>\n\n\n\n
  • Margin Sustainability:<\/strong> Director Munjal Patel<\/strong> noted that a better product mix and operating discipline supported the current quarter’s profit growth.<\/li>\n\n\n\n
  • Expansion Strategy:<\/strong> The company is focusing on increasing its presence in regulated markets and high-value product lines.<\/li>\n\n\n\n
  • Financial Risk:<\/strong> Management highlighted a debt-free balance sheet and a net worth of approximately \u20b9671 crore as of the last audited period.<\/li>\n<\/ul>\n\n\n\n

    Guidance & Outlook<\/strong><\/h2>\n\n\n\n

    Management indicated an objective of sustaining a 15-18% annual growth rate<\/strong>. Factors to watch include the expansion into new geographical markets and the development of over 700 products<\/strong> currently in the pipeline. The company\u2019s performance remains subject to regulatory environments in both domestic and export markets.<\/p>\n\n\n\n

    Performance Summary<\/strong> <\/h2>\n\n\n\n

    Lincoln Pharmaceuticals stock ended the day down 1.26%<\/strong> at \u20b9618.60<\/strong>. Third-quarter net profit increased by 37.70%<\/strong> to \u20b928.60 crore<\/strong> on a 13.49%<\/strong> rise in revenue. The company maintains a debt-free status and is targeting continued expansion in chronic therapy segments.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Lincoln Pharmaceuticals Ltd (LINCOLN:NSE, 531633:BSE) shares closed at \u20b9618.60 on Wednesday, representing a 1.26% decline from the previous session’s close. The pharmaceutical manufacturer’s equity performance follows the release of its financial results for the quarter ended December 31, 2025 (Q3 2026). Market Capitalization As of February 18, 2026, the market capitalization of Lincoln Pharmaceuticals stands […]<\/p>\n","protected":false},"author":2392,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,392,5747],"tags":[10169,14492,16641],"class_list":["post-181260","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-earnings","tag-financial-results","tag-lincoln"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":152372,"url":"https:\/\/alphastreet.com\/india\/lincoln-pharmaceuticals-ltd-q1fy24-27-rise-in-profits\/","url_meta":{"origin":181260,"position":0},"title":"Lincoln Pharmaceuticals Ltd Q1FY24; 27% rise in Profits","author":"Karan_Singh","date":"August 10, 2023","format":false,"excerpt":"Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products. Financial Results: Lincoln Pharmaceuticals Ltd reported Revenues for Q1FY24 of \u20b9136.00 Crores up from \u20b9123.00 Crore year on year, a rise of 10.57%. Total Expenses for Q1FY24 of \u20b9118.00 Crores up from \u20b9109.00\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-568.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-568.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-568.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-568.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-568.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-568.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177028,"url":"https:\/\/alphastreet.com\/india\/senores-pharmaceuticals-shares-gain-after-quarterly-profit-rise\/","url_meta":{"origin":181260,"position":1},"title":"Senores Pharmaceuticals Shares Gain After Quarterly Profit Rise","author":"Staff Correspondent","date":"January 20, 2026","format":false,"excerpt":"Senores Pharmaceuticals Ltd. (NSE: SENORES; BSE: 544319) shares closed 4.85% higher on the National Stock Exchange and Bombay Stock Exchange today, following the release of the company\u2019s third-quarter financial results. The stock recovery follows a period of volatility in the pharmaceutical sector. Market Capitalization The total market capitalization of Senores\u2026","rel":"","context":"In "Health Care"","block_context":{"text":"Health Care","link":"https:\/\/alphastreet.com\/india\/category\/healthcare-stocks\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":141223,"url":"https:\/\/alphastreet.com\/india\/alembic-pharmaceuticals-ltd-nse-aplltd-q3-fy23-results-out-total-income-rises-18-yoy\/","url_meta":{"origin":181260,"position":2},"title":"Alembic Pharmaceuticals LTD. (NSE: APLLTD): Q3 FY23 Results Out; Total Income Rises 18% YoY","author":"Divyansh_Kasana","date":"February 13, 2023","format":false,"excerpt":"Alembic Pharmaceuticals Ltd. (NSE:APLLTD) is an Indian pharmaceutical company that was founded in 1907. It is headquartered in Vadodara, Gujarat, and operates globally. The company specializes in the manufacturing of a wide range of pharmaceutical products, including active pharmaceutical ingredients, formulations, and nutraceuticals. Alembic Pharmaceuticals is known for its high-quality\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":142579,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-glenmark-pharmaceuticals-limited-for-q3-fy23\/","url_meta":{"origin":181260,"position":3},"title":"Earnings Summary Of Glenmark Pharmaceuticals Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 23, 2023","format":false,"excerpt":"Glenmark Pharmaceuticals Limited (NSE: GLENMARK) is a global research-driven pharmaceutical company that develops and markets innovative drugs for major therapeutic areas such as dermatology, respiratory, oncology, and diabetes. The company operates in over 80 countries and has manufacturing facilities in India, Switzerland, and Argentina. The company's revenue is primarily generated\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":142467,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-glaxosmithkline-pharmaceuticals-limited-for-q3-fy23\/","url_meta":{"origin":181260,"position":4},"title":"Earnings Summary Of GlaxoSmithKline Pharmaceuticals Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 22, 2023","format":false,"excerpt":"GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO) is a leading pharmaceutical company in India that develops, manufactures, and markets a range of pharmaceutical products for various therapeutic areas. The company has a strong presence in India and a significant global footprint, with operations in more than 150 countries. In terms of earnings,\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-2.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-2.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-2.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-2.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-2.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-2.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":146522,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-glaxosmithkline-pharmaceuticals-limited-for-q4-fy23\/","url_meta":{"origin":181260,"position":5},"title":"Earnings Summary Of Glaxosmithkline Pharmaceuticals Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 17, 2023","format":false,"excerpt":"GlaxoSmithKline Pharmaceuticals Limited is a renowned Indian pharmaceutical company that operates in the research, development, manufacturing, and marketing of a wide range of prescription medicines, vaccines, and consumer healthcare products. As a subsidiary of the global healthcare giant Glaxosmithkline, the company carries forward its legacy of innovation, quality, and commitment\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/181260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2392"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=181260"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/181260\/revisions"}],"predecessor-version":[{"id":181264,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/181260\/revisions\/181264"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=181260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=181260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=181260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}